InMed Pharmaceuticals Inc (INM)

[robinandthe7hoods]

Short squeeze in effect....

Buy-ins.net-------

November 20, 2017

We are initiating coverage on InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN) after reviewing the daily short volume data aggregated from 14 US stock exchanges and including both EXEMPT (market makers) and NON-EXEMPT (everyone else). 40.79% of the total trading volume in IMLFF has been short selling. Nearly $30 mllion in total has been shorted at an average price of $0.3295. Approximately 90 million total shares have been shorted since we began tracking the activity. A short squeeze is underway as the stock is above its SqueezeTrigger Price. Here is a recent news on the company:

https://finance.yahoo.com/quote/IMLFF/press-releases?p=IMLFF

InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, engages in the research and development of novel and cannabinoid-based therapies in Canada. The company?s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma. It is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory. InMed Pharmaceuticals Inc. has an agreement with Pharmaseed Ltd to develop a final formulation for a topical cannabinoid product candidate intended as a therapy in epidermolysis bullosa (EB) and other dermatological and wound-healing applications; and a research and development collaboration agreement with ATERA SAS to develop 3D human skin models of EB, as well as to evaluate the in vitro drug efficacy of InMed?s lead compound, INM-750. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.